Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2006

View Archived Issues

Nalmefene shows promise in treating pathological gambling / News in Context

NXY-059 appears to reduce disability in ischemic stroke patients

LRH-1 activation: Potential efficacy as a treatment for atherosclerosis

New localized radiotherapeutic for prostate cancer

Capsaicin patch reduces pain in HIV-associated distal sensory polyneuropathy

GCPII inhibitor targeted for neuroprotection and prostate cancer

Neurochem completes rolling NDA for Fibrillex in AA amyloidosis

Phase I study of lemuteporfin in BPH fails to meet primary efficacy objective

Santen updates status of ophthalmic programs

ProMetic BioSciences cleared for Canadian phase Ib/II study of PBI-1402

Ranbaxy and CIH establish joint venture for antiretrovirals in South Africa

Eltrombopag begins phase III trials for ITP

Avant's typhoid fever vaccine Ty-800 studied in new phase I/II trial

BioXell and Lay Line Genomics sign agreement for MNAC13

European COMP recommends orphan drug designation for 1D09C3

Orthokine approved in E.U.

Glenmark discovers new drug targeting obesity

Retapamulin NDA under FDA review

Pfizer looks to value drivers to grow business

Prophylactic and therapeutic efficacy of targeting TLR9 for HSV-2

Recent Incyte patent describes new therapeutic agents for HIV infection

New agents for endocrine-related disorders imparted in recent patent literature

Orphan drug designation for TRX-4 in type 1 diabetes

Phase Ib trial investigates AP-23573 plus doxorubicin for cancer

MB-07803 studied in phase I for type 2 diabetes

New therapeutic agents described for cardiovascular disorders

Japanese phase II trial for gaboxadol

Ambrisentan use in PAH patients who discontinue other ERA therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...